Teva Pharmaceutical Industry Ltd.’s first-quarter earnings call on May 9 was a bit awkward, with outgoing CEO Shlomo Yanai presiding, and incoming CEO Jeremy Levin adhering to mostly stock comments, before being interrupted by a technical snafu that required everyone to dial back in. That said, Levin made one revelation: a review of the company’s previously announced 2012 financial performance estimates was under way.
Barely two weeks later, on May 24, in a hastily scheduled call, Levin was on the phone again with analysts,...